The original promise was intoxicating. Resveratrol -- a polyphenol found in red wine, grapes, and peanuts -- appeared to activate SIRT1, the same longevity pathway triggered by caloric restriction. In yeast, it extended lifespan by 70%. In obese mice, it prevented metabolic disease and improved survival.
Then came the translation problem. Human biology is not yeast biology. The doses that worked in mice -- roughly 22.4 mg per kilogram of body weight -- would require a 180-pound person to consume over 1,800 mg daily. That is the equivalent of drinking approximately 1,000 bottles of red wine per day.
And even at supplement doses of 500-1,000 mg, resveratrol's bioavailability is abysmal. Your liver metabolizes it almost immediately. Less than 1% of what you swallow reaches your bloodstream in its active form. The molecule works brilliantly in a test tube. Getting it to work inside a living human is a different problem entirely.
In 2008, pharmaceutical giant GlaxoSmithKline acquired Sirtris Pharmaceuticals for $720 million. Sirtris was built entirely around resveratrol-based drug development. The plan was to create synthetic, more potent versions of resveratrol for treating type 2 diabetes and aging-related diseases.
By 2010, GSK had halted the lead clinical compound, SRT501, after liver toxicity concerns in a multiple myeloma trial. By 2013, they dissolved Sirtris entirely. Seven hundred and twenty million dollars, gone. Not because the sirtuin theory was wrong, but because resveratrol was the wrong vehicle to test it.
While resveratrol was flaming out in clinical trials, its lesser-known cousin was quietly compiling a more impressive resume. Pterostilbene, found naturally in blueberries and grapes, has the same sirtuin-activating mechanism as resveratrol but with roughly 4x the bioavailability.
The difference is structural. Pterostilbene has two methyl groups where resveratrol has hydroxyl groups, making it more lipophilic -- it crosses cell membranes more easily and resists liver metabolism longer. Studies show oral pterostilbene reaches meaningful plasma concentrations at doses of 50-100 mg, a fraction of the resveratrol dose needed for comparable effects.
It is not a miracle molecule either. But it is a better-designed version of the same idea.
Resveratrol is not worthless. It has genuine antioxidant and anti-inflammatory properties. Some clinical data supports modest cardiovascular benefits at 150-500 mg daily. It may improve insulin sensitivity in overweight individuals.
But as a longevity drug? The dream that launched a thousand supplement brands? That version of resveratrol was always more marketing than molecule. The sirtuin pathway is real. Caloric restriction mimetics are a legitimate area of research. Resveratrol just turned out to be a lousy delivery mechanism for a great idea.
Sometimes the truth about a supplement is that it pointed us in the right direction while being the wrong tool for the job. That is resveratrol's legacy -- not a failure, but a first draft.
Science-backed health tips delivered every week.